Celldex Therapeutics diskutieren
Celldex Therapeutics
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
32,60 €
-4,12 %
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $54.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Wells Fargo & Company. They set an "underweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $54.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $54.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target lowered by analysts at Cantor Fitzgerald from $54.00 to $52.00. They now have an "overweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at HC Wainwright from $73.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at TD Cowen. They set an "outperform" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Neueste Beiträge
Chardan_Capital in iBio Inc. diskutieren